Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Randomized, Controlled, Human Influenza A (H1N1) Challenge Study Following Administration of an Oral H1N1 HA Adenoviral-Vector Based Seasonal Influenza Vaccine and dsRNA Adjuvant to Healthy Adult Volunteers

Next Previous
X
Search
Trial Profile

Phase 2 Randomized, Controlled, Human Influenza A (H1N1) Challenge Study Following Administration of an Oral H1N1 HA Adenoviral-Vector Based Seasonal Influenza Vaccine and dsRNA Adjuvant to Healthy Adult Volunteers

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VXA-A1-1 (Primary) ; Influenza virus vaccine
  • Indications Influenza A virus H1N1 subtype
  • Focus Therapeutic Use
  • Acronyms Challenge
  • Sponsors Vaxart

    • Most Recent Events

    • 18 Nov 2021 Results presented in a Vaxart media release.
    • 22 Jan 2020 According to a Vaxart media release, results were published in the Lancet Infectious Diseases, January 21, 2020 and currently available at doi.org/10.1016/S1473-3099(19)30584-5.
    • 22 Jan 2020 Results presented in a Vaxart Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top